The Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals With Obesity

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The present study evaluates appetite, glucose metabolism, gastrointestinal motility and energy expenditure in men and women with obesity (BMI 30-40 kg/m2) under oxytocin exposure compared to placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Age 18-65 years

• BMI between 30 and 40 kg/m2 (both included)

• Percentage body fat (BF%) ≥25 for men and ≥32 for women (assessed by bioelectrical impedance analysis)

• Informed oral and written consent

Exclusion Criteria:

• Anaemia (haemoglobin below normal range)

• Alanine aminotransferase (ALT) >2 times normal values

• History of hepatobiliary and/or gastrointestinal disorder(s)

• Kidney disease (serum creatinine above normal range and/or urine albumin-creatinine ratio (uACR) >30 mg/g confirmed by two measures)

• Previous gastric or intestinal resection, cholecystectomy and/or any major intra-abdominal surgery (including bariatric surgery)

• Previous pancreatic disease and/or neoplasia

• Regular tobacco smoking and/or use of other nicotine products

• Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment

• Pituitary gland disorders

• Initiation of special diets, lifestyle changes and/or weight loss >5% of total body weight within three months prior to or during study period

• Pregnancy or breastfeeding

• Long QTc on electrocardiogram (ECG) at screening (≥0.45 seconds for men and ≥0.46 seconds for women)

• Any physical or psychological condition or ongoing medication the investigator group suspect would interfere with trial participation